← All companies
About this company
NLS Pharmaceutics Ltd. is a privately owned, Swiss-based biotech firm focusing on the development of new treatments for sleep disorders, such as narcolepsy, ADHD, cognitive impairment and other neurological disorders that remain largely under-diagnosed and for which unmet medical needs are significant. NLS has built a large portfolio of promising non-clinical and clinical-stage compounds, developed by an experienced team of proven experts in ADHD and narcolepsy and working closely with key opinion leaders. NLS’ lead compound, mazindol C.R., has received Orphan Drug Designation both in the U.S. and in Europe for treating narcolepsy and completed a phase 2 study in the U.S. in adult subjects with ADHD demonstrating best-in-class efficacy and a favorable safety profile.